CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

April 18th 2025

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis

April 17th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Dr Farid on the Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 16th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Dr Choi on Advances With Cell Therapy in Hematologic Malignancies

April 14th 2025

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

April 12th 2025

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma

April 11th 2025

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies

April 9th 2025

As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic malignancies.

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance

April 7th 2025

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 3/30

April 5th 2025

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL

April 4th 2025

A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.

Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 3rd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL

April 3rd 2025

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma

April 1st 2025

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.